March 05, 2015 5:53 PM ET

Biotechnology

Company Overview of Clearside BioMedical, Inc.

Company Overview

Clearside BioMedical, Inc., an ophthalmic company, specializes in the research, development, and commercialization of therapeutic products through an ocular microinjection platform that targets the individual compartments of the eye. It provides a non-surgical application for dosing drugs to distinct eye tissues, such as retina, trabecular meshwork, and corneal stroma. The company’s CLS1001 is under development for retinal applications through the delivery of therapeutics to the suprachoroidal space. Clearside BioMedical was incorporated in 2011 and is based in Atlanta, Georgia.

Atlanta, GA 

United States

Founded in 2011

Key Executives for Clearside BioMedical, Inc.

Chief Executive Officer and President
Age: 46
Chief Financial Officer
Age: 49
Executive Vice President of Research and Development
Vice President of Research and Development
Age: 48
Director of Research
Compensation as of Fiscal Year 2014.

Clearside BioMedical, Inc. Key Developments

Clearside Biomedical, Inc. Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment

Clearside Biomedical, Inc. announced the enrollment of the first patient in a Phase 2 randomized, controlled, masked, multi-center clinical trial for the treatment of macular edema associated with retinal vein occlusion (RVO) using Clearside's proprietary formulation of triamcinolone acetonide, CLS-TA, administered via suprachoroidal (SCS) injection using Clearsideâ s proprietary microinjector. Approximately 40 patients will be enrolled at 10 sites in the United States for the Phase 2 clinical trial. All patients will receive one intravitreal injection of Eylea and will be randomized on a 1:1 basis to receive a suprachoroidal injection of either CLS-TA or a sham procedure in the same visit. After randomization, patients will be seen in the clinic once per month for three months. Patients in either treatment arm will be evaluated at the subsequent visits one-, two- and three-months after the initial assigned treatment to receive additional intravitreal injections of Eylea, if they continue to experience macular edema or reductions in visual acuity. If they do not experience increases in macular edema or reductions in visual acuity at these subsequent visits, they will not receive additional intravitreal Eylea treatments. The primary objective of this study is to determine if a single suprachoroidal injection of CLS-TA administered along with an intravitreal injection of Eylea, compared to a single intravitreal injection of Eylea alone, will decrease the need for additional intravitreal Eylea treatments over three months.

Clearside BioMedical, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Clearside BioMedical, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

Clearside BioMedical, Inc. Presents at Nomura Biotechnology Conference, Nov-06-2014 10:00 AM

Clearside BioMedical, Inc. Presents at Nomura Biotechnology Conference, Nov-06-2014 10:00 AM. Venue: The Mandarin Oriental Hotel, 776 Boylston Street, Boston, MA 02199, United States. Speakers: Glenn Noronha, Executive Vice President of Research and Development.

Similar Private Companies By Industry

Company Name Region
Signase, Inc United States
PAPGENE, INC. United States
APE-BridgePath Scientific, LLC United States
IDM, Inc. United States
Genzyme Corporation United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
August 29, 2014
--
Private Placement
April 28, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Clearside BioMedical, Inc., please visit www.clearsidebio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.